Jacob Leach on clinical studies
From BONUS Episode: Dexcom Updates & News from ADA with CEO Jake Leach · · Diabetes Connections
“We have our connect study that we'll be presenting the results later this afternoon. That is a study in people with type 2 diabetes that use other glucose-lowering medications, not using, you know, not insulin. So, GLP-1s, SGLT2s, and then a portion of the folks in this study don't use anything, no medications. They're all using diet and exercise lifestyle to manage diabetes. And so, it's a study, large randomized control trial. The goal is to show the impact of CGM in this population, which that hasn't been done in a randomized control trial of this size.”
On , Jacob Leach, Interim Chief Executive Officer, President & Chief Operating Officer at DexCom Inc, spoke about clinical studies during BONUS Episode: Dexcom Updates & News from ADA with CEO Jake Leach on Diabetes Connections.
About Jacob Leach
Jacob Leach, interim chief executive officer, president, and chief operating officer of Dexcom, has been discussing the company’s product development and reliability efforts in several recent interviews and earnings calls. At the American Diabetes Association conference in June 2026, Leach said Dexcom was presenting results from its Connect study, a randomized controlled trial examining the impact of continuous glucose monitoring (CGM) in people with type 2 diabetes who use non-insulin glucose-lowering medications or manage their condition through diet and exercise. He also noted that Dexcom had acquired Nutrisense, a company focused on nutritional coaching guided by CGM, and that the company is developing a product for hospital use, as no continuous sensor has been approved for subcutaneous use in U.S. inpatient settings. Leach stated that Dexcom is working on a sensor that can measure potassium, citing a lack of at-home testing options for that analyte. Leach has also addressed sensor reliability and customer support. In interviews, he said that the number one reason people stop using a CGM is a perception that glucose data is not reliable, and that Dexcom is focused on improving that. He described changes to the company’s organization, including the addition of a chief product officer responsible for the user experience from initial awareness through product support. Leach said Dexcom is developing a new G8 platform, which he described as half the size of the G7 and featuring technology that allows the sensor to self-adjust during wear without requiring finger-stick calibration. On earnings calls, Leach reported that Dexcom had more than 3.5 million active users and grew its user base by 20% in the prior year. He also noted that the company raised its 2025 revenue guidance to a range of $4.63 billion to $4.65 billion, representing approximately 15% growth, while lowering its non-GAAP gross profit margin guidance to approximately 61%.